This is the authors' abstract. We don't add key points for this paper.
Therapy for diarrhoea associated with the carcinoid syndrome is often unsatisfactory. In an open study ICS 205-930 (Sandoz Limited), a novel 5HT3-antagonist, controlled diarrhoea in five of six patients studied. This drug may be a useful advance in the symptomatic treatment of the carcinoid syndrome.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Coupé et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: